샘플 요청 목록

 카트 문의
시장보고서
상품코드
1610878

세계의 오소바이오로직스 시장 : 인사이트, 경쟁 환경 및 시장 예측(-2030년)

Orthobiologics - Market Insights, Competitive Landscape, and Market Forecast - 2030
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

오소바이오로직스 시장 규모는 2023년 53억 3,000만 달러에 달했습니다. 이 시장은 2024년부터 2030년까지 예측 기간 동안 4.44%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 68억 4,000만 달러에 달할 것으로 예상됩니다. 척추 손상을 유발하는 외상 및 사고 사례 증가, 골관절염 및 류마티스 관절염과 같은 퇴행성 뼈 질환의 유병률 증가, 스포츠 관련 부상 사례 증가는 2024년부터 2030년까지 예측 기간 동안 정형외과용 바이오로직스 시장 수요를 증가시키는 주요 요인으로 작용할 것으로 예상됩니다. 으로 작용하고 있기 때문에 크게 성장하고 있습니다.

세계보건기구(WHO)에 따르면(2024년), 2021년 전 세계 1,540만 명이 척수 손상을 앓고 있는 것으로 추정됩니다. 대부분의 척수 손상은 낙상을 포함한 외상이나 폭력적인 행위로 인해 발생하므로 예방이 가능합니다. 또한, 2023년에는 5세에서 29세 사이의 어린이와 젊은 성인의 사망 원인 중 1위가 교통사고로 인한 사망이 될 것으로 예상되고 있습니다. 또한, 매년 전 세계적으로 2,000만 명에서 5,000만 명에 가까운 사람들이 교통 사고로 인한 비 치명적인 부상을 입어 장애를 입습니다고 밝혔습니다.

세계보건기구(WHO) 데이터(2023년)에 따르면, 전 세계적으로 3억 4,400만 명이 골관절염을 앓고 있습니다. 이 중 골관절염 환자의 73%는 55세 이상이며, 60%는 여성입니다. 골관절염은 무릎 관절의 연골 파괴를 특징으로 하는 퇴행성 관절 질환으로 통증, 뻣뻣함, 운동 범위의 감소를 초래합니다. 같은 자료에 따르면 1,300만 명이 류마티스 관절염을 앓고 있다고 합니다. 관절 내벽에 염증이 생기고 침식되어 연골과 뼈의 파괴가 진행됩니다.

오소바이오로직스는 치유를 촉진하고 증상을 완화하기 위해 다양한 근골격계 질환에 사용되고 있습니다. 척수 손상에서 신경 재생과 회복을 촉진하기 위해 실험적으로 사용되었습니다. 골관절염과 류마티스 관절염의 경우, 다혈소판 혈장 및 줄기세포와 같은 생물학적 제제는 염증을억제하고 연골의 회복을 돕는 것을 목표로 합니다. 스포츠 및 레크리에이션 부상에서 이러한 치료법은 회복을 가속화하고 손상된 조직을 복구하는 데 도움이 될 수 있습니다. 또한, 조직 재생을 촉진하고 염증을억제하여 요통 및 기타 근골격계 질환을 치료하는 데도 오르소바이오틱스가 활용되고 있습니다.

따라서 2024년부터 2030년까지 예측 기간 동안 위의 요인들이 종합적으로 전체 오소바이오로직스 시장을 견인할 것으로 보입니다.

이 보고서는 세계 오소바이오로직스 시장을 조사했으며, 시장 개요와 함께 제품 유형별, 용도별, 최종사용자별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 오소바이로직스 시장 보고서 서론

제2장 오소바이로직스 시장 주요 요약

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 오소바이로직스 시장의 주요 요인 분석

  • 오소바이로직스 시장 성장 촉진요인
  • 오소바이로직스 시장 성장 억제요인과 과제
  • 오소바이로직스 시장 기회

제6장 오소바이로직스 시장 : Porter의 Five Forces 분석

제7장 오소바이로직스 시장 평가

  • 제품 유형별
  • 용도별
  • 최종사용자별
  • 지역별

제8장 오소바이로직스 시장 기업과 제품 개요

  • Medtronic
  • Stryker
  • Johnson & Johnson Services, Inc.
  • Arthrex, Inc.
  • Zimmer Biomet
  • Baxter
  • Orthofix Medical Inc.
  • TERUMO BCT, INC.
  • Sanofi
  • Bioventus
  • Collagen Matrix, Inc.
  • Seikagaku Corporation
  • NuVasive Inc.
  • Exactech, Inc.
  • Fidia Farmaceutici S.p.A
  • BONESUPPORT AB
  • Kuros Biosciences
  • XTANT MEDICAL
  • Biomatlante
  • Globus Medical

제9장 KOL(Key Opinion Leader)의 견해

제10장 프로젝트 접근

제11장 DelveInsight에 대해

제12장 면책사항과 문의

LSH 24.12.24

Orthobiologics Market by Product Type (Viscosupplementation Products, Demineralized Bone Matrices, Bone Morphogenic Protein, Synthetic Bone Substitutes, Bone Grafts, and Others), Application (Osteoarthritis, Spinal Fusion, Soft-Tissue Injuries, Fracture Recovery, and Maxillofacial & Dental Applications), End-User (Hospitals, Orthopaedic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the rising number of trauma & accident cases and increase in the prevalence of degenerative bone disorders across the globe

The orthobiologics market was valued at USD 5.33 billion in 2023, growing at a CAGR of 4.44% during the forecast period from 2024 to 2030, to reach USD 6.84 billion by 2030. The orthobiologics market is growing significantly due to the rising number of trauma and accident cases that cause spinal injuries, increase in prevalence of degenerative bone disorders such as osteoarthritis and rheumatoid arthritis, and rising instances of sports-related injuries that are acting as major factors escalating the demand for orthobiologics market during the forecast period from 2024 to 2030.

Orthobiologics Market Dynamics:

According to the World Health Organization (2024) in 2021, 15.4 million people were living with spinal cord injuries globally. Most cases of spinal cord injury result from trauma, including falls, or acts of violence, and are therefore preventable. Moreover, in 2023, it was stated that road traffic injuries were the leading cause of fatality in children and young adults in the age group of 5-29 years. The same factsheet further stated that nearly 20-50 million people suffer from non-fatal injuries in road accidents resulting in a disability as a result of their injury globally each year.

As per data from the World Health Organization (2023), 344 million individuals were affected by osteoarthritis globally. Among this population, 73% of people living with osteoarthritis are older than 55 years, and 60% are female. Osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage in the knee joint, leading to pain, stiffness, and reduced range of motion. As per the same source, 13 million people were living with rheumatoid arthritis. This causes the joint lining to become inflamed and eroded, leading to progressive destruction of the cartilage and bone.

According to the National Safety Council (2024), it stated that in 2023, emergency departments treated 3.7 million people for injuries related to sports and recreational equipment. The activities most often led to these injuries were exercise, cycling, and basketball. Furthermore, it stated that injuries from exercise and exercise equipment went up by 8% in 2023, with 482,886 injuries compared to 445,642 in 2022. The highest injury rate was among 15 to 24-year-olds.

The World Health Organization in the year 2022 stated that approximately 1.71 billion people were affected by musculoskeletal conditions worldwide. Further it stated that low back pain is the main contributor to the overall burden of musculoskeletal conditions which contributes to 570 million prevalent cases worldwide. Musculoskeletal conditions, affecting a significant portion of the global population, often include low back pain as a major issue.

Orthobiologics are employed in various musculoskeletal conditions to enhance healing and alleviate symptoms. For spinal cord injuries, they are used experimentally to promote nerve regeneration and repair. In osteoarthritis and rheumatoid arthritis, orthobiologics like platelet-rich plasma and stem cells aim to reduce inflammation and support cartilage repair. For sports and recreational injuries, these therapies help accelerate recovery and repair damaged tissues. Additionally, orthobiologics are utilized to treat low back pain and other musculoskeletal issues by promoting tissue regeneration and reducing inflammation.

Therefore, the factors stated above collectively will drive the overall orthobiologics market during the forecast period from 2024 to 2030.

However, the availability of alternative therapies and stringent regulatory approvals among others may limit their end-user base, thus acting as key constraints limiting the growth of the orthobiologics market.

Orthobiologics Market Segment Analysis:

Orthobiologics Market by Product Type (Viscosupplementation Products, Demineralized Bone Matrices, Bone Morphogenic Protein, Synthetic Bone Substitutes, Bone Grafts, and Others), Application (Osteoarthritis, Spinal Fusion, Soft-Tissue Injuries, Fracture Recovery, and Maxillofacial & Dental Applications), End-User (Hospitals, Orthopaedic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of orthobiologics, the bone grafts category is expected to have a significant revenue share in the year 2023. The rapid growth of this product category can be attributed to the features associated with this category.

The bone grafts provide structural support, promote new bone formation, and facilitate the healing of fractures or defects. Applications include spinal fusions, where bone grafts support vertebral stabilization; repair of complex fractures or bone loss due to trauma and reconstruction following tumor removal.

Additionally, bone grafts are utilized in dental implant procedures and orthognathic surgeries to restore bone volume and function. Their versatility and effectiveness make them essential tools in managing a wide array of orthopedic and dental conditions, enhancing recovery and long-term outcomes.

Rising product developmental activities by the regulatory body are also likely to drive the market for same. For example in February 2022, Orthofix Medical introduced Opus BA, a synthetic bioactive bone graft solution designed for cervical and lumbar spine fusion procedures. This launch marks the company's expansion in synthetic bone growth solutions.

Therefore, owing to all the above-mentioned factors, the demand for the bone grafts category upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the orthobiologics market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall orthobiologics market:

Among all the regions, North America is expected to dominate the orthobiologics market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This can be ascribed to the growing burden of total knee replacement surgeries due to conditions like gout, increased instances of vertebral compression fractures, and hip fractures, coupled with ongoing advancements in medical technology and a robust healthcare infrastructure in the region that drives the market for orthobiologics during the forecast period from 2024 to 2030.

According to data from the American Academy of Orthopaedic Surgeons in 2024, it stated that over 700,000 total knee replacement surgeries were performed each year in the US. In addition to this, recent updates provided by the Arthritis Society Canada (2022), stated that 1 million Canadians were affected by gout, which is the most common form of inflammatory arthritis. Gout predominantly impacts males more than females, with approximately 4% of men and 1% of women affected. Among the various joints that can be affected, the knee joint is the most commonly involved.

According to the National Institute of Health (2023), it stated that vertebral compression fractures (VCFs) are the most frequently reported type of fragility fracture. In the US, approximately 1 to 1.5 million VCFs occur each year. Studies suggest that about 25% of women aged 50 and older have at least one VCF. Additionally, between 40% and 50% of individuals over the age of 80 are estimated to have experienced a VCF, either as an acute event or discovered incidentally during the evaluation of other health issues.

According to data from the American Academy of Orthopaedic Surgeons (2024), annually, over 300,000 individuals in the U.S. experience a hip fracture, with the majority occurring in those aged 65 and older due to falls in the home or community. In addition to this, the National Institute of Health (2023) stated that in the US, avascular necrosis of the femoral head is estimated to affect between 20,000 and 30,000 new patients each year.

Orthobiologics play a significant role in various orthopedic conditions mentioned above. In total knee replacement surgeries and knee-related issues caused by arthritis or gout, orthobiologics like platelet-rich plasma and stem cells are used to promote cartilage repair, reduce inflammation, and improve healing outcomes. For VCFs, orthobiologics such as bone grafts and bone morphogenetic proteins are utilized to enhance bone healing and support spinal stability. In hip fractures and conditions like avascular necrosis of the femoral head, orthobiologics aid in bone regeneration and improve recovery by promoting blood supply and new bone growth.

Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the orthobiologics market.

Orthobiologics Market key players:

Some of the key market players operating in the orthobiologics market include Medtronic, Stryker, Johnson & Johnson Services, Inc., Arthrex, Inc., Zimmer Biomet, Baxter, Orthofix Medical Inc., TERUMO BCT, INC., Sanofi, Bioventus, Collagen Matrix, Inc., Seikagaku Corporation, NuVasive Inc., Exactech, Inc., Fidia Farmaceutici S.p.A, BONESUPPORT AB, Kuros Biosciences, XTANT MEDICAL, Biomatlante, Globus Medical, and others.

Recent Developmental Activities in the Orthobiologics Market:

  • In June 2023, BONESUPPORT(TM), an emerging leader in orthobiologics for managing bone injuries, announced the launch of the next generation of the company's breakthrough antibiotic-eluting bone graft substitute, CERAMENT G.
  • In March 2022, SeaSpine announced the launch of its NorthStar cervical facet fusion and Flash navigation lumbar facet fusion systems. These new offerings were designed to enhance spinal surgery by providing advanced solutions for cervical and lumbar facet fusion procedures.
  • In July 2021, Orthofix Medical Inc., launched the fiberFUSE strip, an advanced demineralized fiber bone graft solution containing cancellous bone in the US.
  • In July 2021, RTI Surgical entered into a long-term strategic agreement with Exactech for the development and supply of biologic bone substitutes. As part of the agreement, RTI Surgical acquired Exactech's Optecure(R), a 510(k)- cleared demineralized bone matrix for use as a bone graft extender in the spine, pelvis, and extremities.

Key Takeaways from the Orthobiologics Market Report Study

  • Market size analysis for current orthobiologics market size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the orthobiologics market
  • Various opportunities available for the other competitors in the orthobiologics market space
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current orthobiologics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for orthobiologics market growth in the coming future?

Target audience who can be benefited from this Orthobiologics Market Report Study

  • Orthobiologics product providers
  • Research organizations and consulting companies
  • Orthobiologics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in orthobiologics
  • Various end-users who want to know more about the orthobiologics market and the latest developments in the orthobiologics market

Frequently Asked Questions for the Orthobiologics Market:

1. What are Orthobiologics?

Orthobiologics are substances used to improve the healing of broken bones and injured muscles, tendons, and ligaments. These products are often made from substances that are naturally found in the body.

2. What is the market for Orthobiologics?

The orthobiologics market was valued at USD 5.33 billion in 2023, growing at a CAGR of 4.44% during the forecast period from 2024 to 2030 to reach USD 6.84 billion by 2030.

3. What are the drivers for the Orthobiologics market?

The orthobiologics market is growing significantly due to the rising number of trauma and accident cases that cause spinal injuries, increase in prevalence of degenerative bone disorders such as osteoarthritis and rheumatoid arthritis, and rising instances of sports-related injuries that are acting as major factors escalating the demand for orthobiologics market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Orthobiologics market?

Some of the key market players operating in the orthobiologics market include Medtronic, Stryker, Johnson & Johnson Services, Inc., Arthrex, Inc., Zimmer Biomet, Baxter, Orthofix Medical Inc., TERUMO BCT, INC., Sanofi, Bioventus, Collagen Matrix, Inc., Seikagaku Corporation, NuVasive Inc., Exactech, Inc., Fidia Farmaceutici S.p.A, BONESUPPORT AB, Kuros Biosciences, XTANT MEDICAL, Biomatlante, Globus Medical, and others.

5. Which region has the highest share in the Orthobiologics market?

Among all the regions, North America is estimated to hold a significant revenue share in the orthobiologics market. This can be ascribed to the growing burden of total knee replacement surgeries due to conditions like gout, increased instances of vertebral compression fractures, and hip fractures, coupled with ongoing advancements in medical technology and a robust healthcare infrastructure in the region that drives the market for orthobiologics during the forecast period from 2024 to 2030.

Table of Contents

1. Orthobiologics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Orthobiologics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Orthobiologics Market Key Factors Analysis

  • 5.1. Orthobiologics Market Drivers
    • 5.1.1. Rising number of trauma and accident cases
    • 5.1.2. Increase in prevalence of degenerative bone disorders
    • 5.1.3. Growing number of sports-related injuries
    • 5.1.4. Rising product developmental activities
  • 5.2. Orthobiologics Market Restraints and Challenges
    • 5.2.1. Availability of alternative therapies
    • 5.2.2. Stringent regulatory approval
  • 5.3. Orthobiologics Market Opportunities
    • 5.3.1. Incorporating orthobiologics with 3D printing technology
    • 5.3.2. Continuous research and development in advanced cellular therapies

6. Orthobiologics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Orthobiologics Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Viscosupplementation Products
    • 7.1.2. Demineralized Bone Matrices
    • 7.1.3. Bone Morphogenic Protein
    • 7.1.4. Synthetic Bone Substitutes
    • 7.1.5. Bone grafts
    • 7.1.6. Others
  • 7.2. By Application
    • 7.2.1. Osteoarthritis
    • 7.2.2. Spinal Fusion
    • 7.2.3. Soft-tissue Injuries
    • 7.2.4. Fracture Recovery
    • 7.2.5. Maxillofacial and Dental Applications
  • 7.3. End-User
    • 7.3.1. Hospitals
    • 7.3.2. Orthopaedic Clinics
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.1.2. Canada Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.1.3. Mexico Orthobiologics Market Size in USD million (2021-2030)
    • 7.4.2. Europe
      • 7.4.2.1. France Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.2.2. Germany Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.2.3. United Kingdom Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.2.4. Italy Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.2.5. Spain Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.2.6. Rest of Europe Orthobiologics Market Size in USD million (2021-2030)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.3.2. Japan Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.3.3. India Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.3.4. Australia Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.3.5. South Korea Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.3.6. Rest of Asia-Pacific Orthobiologics Market Size in USD million (2021-2030)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.4.2. Africa Orthobiologics Market Size in USD million (2021-2030)
      • 7.4.4.3. South America Orthobiologics Market Size in USD million (2021-2030)

8. Orthobiologics Market Company and Product Profiles

  • 8.1. Medtronic
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Stryker
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Johnson & Johnson Services, Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Arthrex, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Zimmer Biomet
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Baxter
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Orthofix Medical Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. TERUMO BCT, INC.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Sanofi
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Bioventus
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Collagen Matrix, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Seikagaku Corporation
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. NuVasive Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Exactech, Inc.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Fidia Farmaceutici S.p.A
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. BONESUPPORT AB
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Kuros Biosciences
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. XTANT MEDICAL
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Biomatlante
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Globus Medical
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제